{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:39Z","timestamp":1791993939386,"version":"4.4.0"},"reference-count":47,"publisher":"Stanford University Press","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jmsacl.2021.11.004","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T12:10:31Z","timestamp":1637928631000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease"],"prefix":"10.21627","volume":"22","author":[{"given":"Hoda Safari","family":"Yazd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina Feizbakhsh","family":"Bazargani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Vanbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"King-Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-2868","authenticated-orcid":false,"given":"Coy","family":"Heldermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Yost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5903-7113","authenticated-orcid":false,"given":"William L.","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-009X","authenticated-orcid":false,"given":"Timothy J.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4811","reference":[{"issue":"4","key":"10.1016\/j.jmsacl.2021.11.004_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal storage disorders","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jmsacl.2021.11.004_b0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7503","key":"10.1016\/j.jmsacl.2021.11.004_b0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jmsacl.2021.11.004_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jmsacl.2021.11.004_b0025","unstructured":"A. Mehta, M. Beck, G. Sunder-Plassmann. Fabry Disease: Perspectives from 5 Years of FOS. 2006."},{"issue":"4","key":"10.1016\/j.jmsacl.2021.11.004_b0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"issue":"4","key":"10.1016\/j.jmsacl.2021.11.004_b0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","volume":"43","author":"Deegan","year":"2006","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.jmsacl.2021.11.004_b0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"issue":"3","key":"10.1016\/j.jmsacl.2021.11.004_b0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","article-title":"Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature","volume":"107","author":"Pisani","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:BOLI.0000028726.11177.8b","article-title":"Clinical benefit in Fabry patients given enzyme replacement therapy\u2013a case series","volume":"27","author":"Guffon","year":"2004","journal-title":"J. Inherit Metab. Dis."},{"issue":"9","key":"10.1016\/j.jmsacl.2021.11.004_b0060","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2018030329","article-title":"Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease","volume":"29","author":"Lenders","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.jmsacl.2021.11.004_b0065","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jmsacl.2021.11.004_b0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.jmsacl.2021.11.004_b0075","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"23-24","key":"10.1016\/j.jmsacl.2021.11.004_b0080","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"Auray-Blais","year":"2010","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb","volume":"41","author":"Alharbi","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0090","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"issue":"19","key":"10.1016\/j.jmsacl.2021.11.004_b0095","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.11.004_b0100","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s13361-014-1060-3","article-title":"Metabolomic discovery of novel urinary galabiosylceramide analogs as Fabry disease biomarkers","volume":"26","author":"Boutin","year":"2015","journal-title":"J. Am. Soc. Mass. Spectrom."},{"issue":"4","key":"10.1016\/j.jmsacl.2021.11.004_b0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.11.004_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biom11020271","article-title":"Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions","volume":"11","author":"Kok","year":"2021","journal-title":"Biomolecules"},{"issue":"21","key":"10.1016\/j.jmsacl.2021.11.004_b0125","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2008.02.050","article-title":"Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results","volume":"51","author":"Linthorst Gabor","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.jmsacl.2021.11.004_b0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0135","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1194\/jlr.R300004-JLR200","article-title":"Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics","volume":"44","author":"Han","year":"2003","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.11.004_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbalip.2003.11.002","article-title":"Lipidomics is emerging","volume":"1634","author":"Lagarde","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"issue":"19","key":"10.1016\/j.jmsacl.2021.11.004_b0145","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/rcm.1170","article-title":"Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry","volume":"17","author":"Lee","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"issue":"11","key":"10.1016\/j.jmsacl.2021.11.004_b0150","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrendo.2016.98","article-title":"Lipidomics for studying metabolism","volume":"12","author":"Han","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/mas.21492","article-title":"Selection of internal standards for accurate quantification of complex lipid species in biological extracts by electrospray ionization mass spectrometry-What, how and why?","volume":"36","author":"Wang","year":"2017","journal-title":"Mass Spectrom. Rev."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.11.004_b0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jssc.201700709","article-title":"Mass-spectrometry-based lipidomics","volume":"41","author":"Hu","year":"2018","journal-title":"J. Sep. Sci."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.11.004_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13167-016-0074-2","article-title":"Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine","volume":"7","author":"G\u00fclbakan","year":"2016","journal-title":"EPMA J."},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0170","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1021\/acs.analchem.9b03522","article-title":"Statistically driven metabolite and lipid profiling of patients from the undiagnosed diseases network","volume":"92","author":"Webb-Robertson","year":"2020","journal-title":"Anal. Chem."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ng.2982","article-title":"The multiple tissue human expression resource, C., an atlas of genetic influences on human blood metabolites","volume":"46","author":"Shin","year":"2014","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.jmsacl.2021.11.004_b0180","doi-asserted-by":"crossref","first-page":"e0127048","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of Lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jmsacl.2021.11.004_b0185","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201519","article-title":"Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease","volume":"40","author":"You","year":"2020","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.jmsacl.2021.11.004_b0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cca.2008.03.021","article-title":"Evaluation of the Bayer microalbumin\/creatinine urinalysis dipstick","volume":"393","author":"Wilde","year":"2008","journal-title":"Clin. Chim. Acta"},{"issue":"Supplement 2","key":"10.1016\/j.jmsacl.2021.11.004_b0195","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.2337\/dc08-s249","article-title":"Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?","volume":"31","author":"Basi","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jmsacl.2021.11.004_b0200","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/ckj\/sft089","article-title":"Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease","volume":"6","author":"Costa","year":"2013","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.11.004_b0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-017-0571-0","article-title":"Ultrastructural deposits appearing as \u201czebra bodies\u201d in renal biopsy: Fabry disease?- comparative case reports","volume":"18","author":"de Menezes Neves","year":"2017","journal-title":"BMC Nephrol."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.11.004_b0210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.47102\/annals-acadmedsg.V38N3p240","article-title":"Drug-induced kidney disease\u2013pathology and current concepts","volume":"38","author":"Loh","year":"2009","journal-title":"Ann. Acad. Med. Singap."},{"issue":"3","key":"10.1016\/j.jmsacl.2021.11.004_b0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.jmsacl.2021.11.004_b0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.jmsacl.2021.11.004_b0225","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/clinchem\/44.12.2401","article-title":"Newborn screening by tandem mass spectrometry: a new era","volume":"44","author":"Levy","year":"1998","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.jmsacl.2021.11.004_b0230","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/TP.0b013e31829c7cec","article-title":"Verification of association of elevated serum IDO enzyme activity with acute rejection and low CD4-ATP levels with infection","volume":"96","author":"Dharnidharka","year":"2013","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.jmsacl.2021.11.004_b0235","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/clinchem\/44.12.2405","article-title":"Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours","volume":"44","author":"Chace","year":"1998","journal-title":"Clin. Chem."}],"container-title":["Journal of Mass Spectrometry and Advances in the Clinical Lab"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X21000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667145X21000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:22:26Z","timestamp":1767770546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667145X21000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"alternative-id":["S2667145X21000298"],"URL":"https:\/\/doi.org\/10.1016\/j.jmsacl.2021.11.004","relation":{},"ISSN":["2667-145X"],"issn-type":[{"value":"2667-145X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Mass Spectrometry and Advances in the Clinical Lab","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmsacl.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of MSACL.","name":"copyright","label":"Copyright"}]}}